Kornimate/medical-research-clean huggingface dataset:
eswt for ue pain in patients with cervical spinal cord injury

Conditions: Spastic Tetraplegia; Pain; Myelopathy Cervical

Summary: this study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (eswt) for upper extremity pain related to spasticity in patients with spinal cord injury.

6 times of eswt (3,000 pulses per time, low energy under 0.3 mj/m\^2, tolerable range) on forearm area to reduce pain related to spasticity in patients with cervical myelopathy

Eligibility criteria:
inclusion criteria: 1. spinal cord damage confirmed in the spinal cord image 2. 1 month after spinal cord injury 3. spasticity of upper extremities 4. pain in areas below spinal cord injury more than 4 points on the numerical scale (nrs) 5. cognitive functions that can clearly point out nrs with more than 15 points in the mini mental state examination (mmse) 6. age: 20 and older 7. person who has agreed in writing to decide his or her participation and comply with the precautions exclusion criteria: 1. pain due to trauma 2. injection treatments two weeks before participating in the study 3. severe coagulopathy (excluding antiplatelet use) 4. impaired cognition

Keywords: extracorporeal shockwave therapy cervical myelopathy spasticity pain
the formulation of compound phellinus igniarius decoction on radiation pneumonitis

Conditions: Radiation Pneumonitis

Summary: the objectives of this clinical trial were to determine the radioprotective effects and underlying biological mechanisms of phellinus igniarius and its active components during radiotherapy in patients with thoracic malignant tumors. the study group was given the formulation of compound phellinus igniarius decoction daily during radiotherapy, 150ml bid until the end of radiotherapy; the control group only received standard dose radiotherapy without the formulation of compound phellinus igniarius decoction intervention. the baseline differences between the two groups were compared, including gender, smoking history, body mass index (bmi), pathological classification, median age of onset, inflammatory factors, tumor markers, tnm stage, kps score, fatigue score, incidence and grade of radiation pneumonitis, incidence of other radiotherapy-related adverse reactions, and average radiation dose.

investigators measured the levels of inflammatory factors and tumor markers in blood samples of patients in the two income groups, and administered questionnaires on the degree of fatigue and general status of patients. metabolite changes and gut microbiota homeostasis in patient fecal samples were then detected by untargeted metabolomics and metagenomics.

Eligibility criteria:
inclusion criteria: * age ≥18 years, ecog score≤2, possess adequate communication and comprehension abilities, and have an anticipated survival time exceeding 6 months * confirmed diagnosis of lung malignancy through imaging and pathological examination * indications for thoracic radiotherapy, dt:50-60gy/20-30f * normal function of vital organs, including the heart, liver, kidneys, and gastrointestinal system exclusion criteria: * patients with pre-existing pulmonary conditions, including idiopathic pulmonary fibrosis * individuals with systemic immune disorders * those with concurrent major infections * patients diagnosed with hematological disorders. all participants provided written informed consent
to evaluate the cardiac safety of pegylated liposomal doxorubicin concurrently plus trastuzumab and pertuzumab in the adjuvant setting for early-stage her-2-positive breast cancer: a multicenter, randomized controlled clinical study

Conditions: Breast Cancer

Summary: to evaluate the safety and efficacy of pegylated liposomal doxorubicin/cyclophosphamide/trastuzumab/pertuzumab followed by docetaxel/ trastuzumab/pertuzumab compared with epirubicin/cyclophosphamide followed by docetaxel/trastuzumab/pertuzumab in the adjuvant treatment of early breast cancer.


Eligibility criteria:
inclusion criteria: 1. 18-70 years old, female; 2. subjects with histopathologically confirmed invasive breast cancer; 3. her2-positive breast cancer (immunohistochemistry score of 3+ or fluorescence in situ hybridization positivity); 4. no distant metastasis; 5. lymph node positive or negative, primary tumour≥2cm; 6. lymph node negative，primary tumour≤2cm and any of the following factors; 1) histological grade 3; 2) er negative (\<10%) and pr negative (\<20%); 3) age\<35 years old; 4) pathological hint: vascular invasion or intravascular cancer thrombus; 7. surgery was completed and chemotherapy was started within 8 weeks after surgery; 8. before and after chemotherapy lvef≥55%; 9. ecog performance status of 0-1; 10. signed the informed consent. exclusion criteria: 1. subjects who are known to be allergic or intolerant to chemotherapy drugs or their excipients; 2. previously suffered from invasive breast cancer, and other malignant tumors within 5 years (excluding carcinoma in situ of the cervix, carcinoma in situ of the rectum, carcinoma in situ of melanoma, basal cell carcinoma of the skin, and squamous cell carcinoma); 3. for breast cancer, have received any anti-tumor therapy before randomization (except surgical treatment before enrollment); 4. hematopoietic function, renal function and liver function meet one of the following conditions: 1) neutrophil count ≤1.5×109/l; 2) platelet count ≤ 50×109/l; 3) hemoglobin ≤ 8.0g/dl; 4) creatinine clearance rate ≤30ml/min; 5) ast and alt ≥ 2.5 times the upper limit of normal in subjects without liver metastases; 6) bilirubin ≥ 2 times the upper limit of normal; 7) aptt/pt≥1.5 times the upper limit of normal; 5. have a history of cardiovascular disease or associated with severe cardiovascular disease, lung disease; 6. active hypertension: systolic blood pressure ≥ 180mmhg, diastolic blood pressure ≥ 90mmhg; 7. nyha cardiac insufficiency grading ≥ ⅲ grade; 8. severe, uncontrollable systemic disease; 9. subjects who are pregnant or breastfeeding, or subjects who cannot ensure effective contraceptive measures during the study treatment; 10. subjects who participated in other clinical trials at the same time; 11. subjects determined by the investigator to be inappropriate to participate in this study.
oxygen therapy for retinal ischemia

Conditions: Retinal Ischemia

Summary: the investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. they will report back in follow up monthly for three to six months.

Eligibility criteria:
inclusion criteria: * diagnosis of retinal-ischemia related condition exclusion criteria: * complicating other ocular condition * history of smoking or lung conditions
effect of carvedilol controlled-release (cr) and atenolol on central blood pressure

Conditions: Hypertension

Summary: the purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm. blood pressure measured in the aorta, a large blood vessel carrying blood away from the heart, may be a better measure of the harmful effects of high blood pressure on the body's organs. in the past, blood pressure has only been measured in the arms. however, blood pressure in the arms may not accurately reflect the blood pressure in the aorta and thus may mislead doctors treating high blood pressure. for this reason, we are testing whether two different medications for blood pressure, both in a class called beta blockers, have similar effects on blood pressure in the arm and aorta.

carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (central study) is a prospective, open-label, comparative, randomized control trial that evaluated brachial and central hemodynamic profiles in patients taking atenolol or controlled-release carvedilol.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * hypertension (untreated or treated with no more then one anti-hypertensive drug) exclusion criteria: * secondary forms of hypertension (including sleep apnea) * patients currently treated with two or more antihypertensive drugs * patients taking antihypertensive drugs with properly measured clinic systolic blood pressure greater then 170mmhg * isolated systolic hypertension * other diseases requiring treatment with blood pressure lowering medications * heart rate less then 55 beats/min (in the absence of beta-blocker therapy) * known cardiovascular disease including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease (including stroke and tia) * known diabetes mellitus (type 1 or 2) * renal insufficiency defined as a serum creatinine greater then 1.5mg/dl in males and 1.4mg/dl in females * primary renal disease * pregnancy or lactation * history of raynaud's syndrome * alcoholism and recreational drug use (due to compliance concerns)
aerosoliserat dnase for treatment of respiratory failure in severe covid-19

Conditions: COVID-19

Summary: recent observations have suggested a role of neutrophil extracellular traps (nets) in the pathophysiology of severe covid-19. the aim of the study is to assess efficacy and safety of aerosolized dnase i to remove nets and decrease respiratory distress in patients with covid-19.

study objectives: primary objective: to compare the treatment effect of aerosolized dnase i to that of placebo (nacl, 0.9%) on time to cessation of oxygen therapy or discharge from hospital in hospitalized patients with covid-19 and respiratory dysfunction. secondary objectives: to compare the treatment effect of aerosolized dnase i to that of placebo (nacl, 0.9%) on 28-day mortality, days alive and without ventilator treatment, days alive and without high flow nasal oxygen treatment (optiflow), length of stay in the icu, days alive and outside hospital, relapse of hypoxia, days alive and without need for supplemental oxygen, adverse reactions. exploratory objectives: to compare the treatment effect of aerosolized dnase i to that of placebo (nacl, 9%) on quantification of nets in respiratory secretions and on the incidence of clinical thromboembolic events. study design: phase 2 open-label randomized controlled multicentre trial. the study period is 28 days from randomization. a long term follow-up on mortality and readmission will also be collected via patient medical records/registries at day 90, day 180, and day 360 after randomization.

Eligibility criteria:
inclusion criteria: * age ≥18 years old * admitted to hospital ward or icu * a positive pcr test for sars-cov-2 from throat swab or nasopharynx * an oxygen saturation ≤90% after maximum 15 minutes without supplemental oxygen * signed informed consent exclusion criteria: * mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation * known or suspected allergy against pulmozyme * chronic obstructive pulmonary disease stage iii-iv or another comparable chronic respiratory disease * participation in a clinical study with an investigational product during the last 30 days * previous participation in this study * pregnancy. women of childbearing potential must agree to use contraceptives for the duration of the study period * any condition that, in the opinion of the investigator, would place the patient at increased risk or preclude the patient's compliance with the study
iodine status in pregnant women and their newborns: is congenital hypothyroidism related to iodine deficiency in pregnancy?

Conditions: Congenital Hypothyroidism; Pregnancy; Iodine Deficiency

Summary: iodine is an essential component of thyroid hormone, which is necessary for many metabolic processes as well as the maturation of the cns. deficiencies of iodine have deleterious effects on both pregnant women and infants. the iodine status of the population after implementation of the universal salt iodization program in zhejiang province has not been known. this study was to determine whether pregnant women show evidence of iodine deficiency, and to examine the correlation between maternal urine iodine concentration and newborn thyroid function.

iodine is an essential component of thyroid hormone, which is necessary for many metabolic processes as well as the maturation of the cns. deficiencies of iodine have deleterious effects on both pregnant women and infants. the iodine status of the population after implementation of the universal salt iodization program in zhejiang province has not been known. this study was to determine whether pregnant women show evidence of iodine deficiency, and to examine the correlation between maternal urine iodine concentration and newborn thyroid function. healthy women at 12 weeks' gestation and over from four different areas in zhejiang province were enrolled to participate this program from may 2007 to may 2010. women consented to provide urine samples and salt samples during pregnancy (12, 16, 24 weeks' gestation and before delivery), and give permission to access their newborn's tsh value. urinary iodine concentration (uic) was determined by ammonium persulfate digestion microplate method, and tsh was determined by a time resolved fluoro-immunoassay (trfia). the diagnostic standard for congenital hypothyroidism was: tsh ≥ 20 mu/l and declined ft4 levels. compare the correlation to effects with different level of iodine content in salt, maternal uic and neonatal tsh. investigate the optimal level of iodine content in salt in different areas in zhejiang province.

Eligibility criteria:
inclusion criteria: * pregnant women in zhejiang province (and their newborns) exclusion criteria: * endocrine disease

Keywords: congenital hypothyroidism pregnancy iodine deficiency
supra-inguinal fascia iliaca compartment block on postoperative management in total hip arthroplasty by posterior approach

Conditions: Arthropathy of Hip

Summary: find the impact of supra-inguinal fascia iliaca compartment block on postoperative pain management after total hip arthroplasty by posterior surgical approach

asa physical status 1, 2 and 3 patients scheduled to undergo elective surgery of total hip arthroplasty under spinal anesthesia. the investigators would like to study the impact of supra-inguinal fascia iliaca block on postoperative pain management after total hip arthroplasty by posterior surgical approach. the principal investigator perform this block with ultrasound technique. the investigators also want to observe if this loco-regional new approach to fascia iliaca block could have influence on opioid side effects, postoperative nausea and vomiting, length of hospitalisation and first mobilisation side effects.

Eligibility criteria:
inclusion criteria: * adults patients scheduled to undergo elective surgery of total hip arthroplasty by posterior surgical aboard exclusion criteria: * patient refusal * allergy to used medications or local infection. * pregnancy * obesity with body mass index \> 35 * history of chronic pain or fibromyalgia * drug (opioids) addiction * treatment with corticosteroids for more than 6 months * severe kidney or liver diseases * mental disorders or serious neurological diseases
the role of the vitamin d receptor gene polymorphisms in hepatocarcinogenesis

Conditions: Liver Cancer

Summary: previous data have suggested that vitamin d levels may influence cancer development. in particular, several single nucleotide polymorphisms have been described in the vitamin d receptor( vdr gene), and some polymorphisms are associated with tumor occurrence. for instance, vdr polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations . vdr polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis b, primary biliary cirrhosis and autoimmune hepatitis . in a recent published study, vdr polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of hcc in patients with chronic hepatitis b. a significant association of vdr (apai) polymorphism with the development of hcc in chronic hcv infection may help to identify those who are at high risk of developing hcc.

hepatitis c virus (hcv) infection is one of the major public health problems worldwide . chronic hcv infection is characterized by a high rate of progression to fibrosis, chronic hepatitis, leading to cirrhosis and ultimately to hepatocellular carcinoma (hcc). early detection is critically important because the most effective treatment for hcc is surgical resection or ablation therapy when the tumour is small. on the other hand, genetic factors can also contribute, particularly gene polymorphisms of inflammatory cytokines and growth factor ligands and receptors . vitamin d is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses, fibrogenesis and development of cancer through vitamin d receptor (vdr). previous data have suggested that vitamin d levels may influence cancer development. in particular, several single nucleotide polymorphisms have been described in the vdr gene, and some polymorphisms are associated with tumor occurrence. for instance, vdr polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations. vdr polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis b, primary biliary cirrhosis and autoimmune hepatitis . in a recent published study, vdr polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of hcc in patients with chronic hepatitis b. a significant association of vdr apai polymorphism with the development of hcc in chronic hcv infection may help to identify those who are at high risk of developing hcc.

Eligibility criteria:
inclusion criteria: * hcv cirrhotic patient with and without hcc exclusion criteria: * malignancy other than hcc * co-infection with hepatitis b virus (hbv) and human immunodeficiency virus (hiv) * cirrhosis is due to causes other than chronic hepatitis c
motivational interventions for lifestyle and exercise in college students

Conditions: Alcohol Consumption

Summary: engagement in substance-free activities, such as exercise, has an inverse relationship to substance use in college students. while exercise has numerous physical and mental health benefits, the majority of college students are sedentary, infrequently engaging in exercise. although exercise interventions to date often suffer from significant attrition and poor adherence, motivational interventions for exercise are beginning to show promise. in this pilot study we propose to develop and evaluate a novel exercise intervention combining motivational enhancement therapy (met) with contingency management (cm) in sedentary college students who use alcohol.


Eligibility criteria:
inclusion criteria: * sedentary college students who drink alcohol. exclusion criteria: * medical contraindications for exercise.

Keywords: exercise college students sedentary college students
transcutaneous afferent patterned stimulation (taps) for reduction of parkinson's disease (pd) related action tremor

Conditions: Parkinson Disease

Summary: demonstrate safety and efficacy of taps delivered by a cala device as a treatment for action tremor in subjects with parkinson's disease hand tremor

40 patients with pd with at least mild postural tremor were enrolled in a four-week, prospective, single-arm, open-label study of twice daily taps therapy. due to the covid-19 pandemic, taps devices were shipped to patients to run the study remotely. unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.

Eligibility criteria:
inclusion criteria: * must be ≥22 years of age * competent and willing to provide written, informed consent to participate in the study * clinically significant postural tremor as defined by: * dominant hand/arm exhibiting postural tremor ≥ 2 (while in the off state) as assessed by the mds-updrs postural tremor score * stable dose of parkinson's disease medications, if applicable, for 30 days prior to study entry * willing to comply with study protocol requirements including: * having the ability to do telemedicine or video calls for study visits * remaining on a stable dosage of parkinson's medications, if applicable, during the duration of the study * no significant caffeine consumption within 8 hours of study visits exclusion criteria: * implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator * suspected or diagnosed epilepsy or other seizure disorder * swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site * peripheral neuropathy affecting the tested upper extremity * presence of any other neurodegenerative disease or dementia. these may include: multisystem atrophy, progressive supranuclear palsy, dementia with lewy bodies, and alzheimer's disease. * botulinum toxin injection for hand tremor within 6 months prior to study enrollment * are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the sponsor * significant caffeine consumption within 8 hours of study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee). * subjects unable to communicate with the investigator and staff * any health condition that in the investigator's opinion should preclude participation in this study * pregnancy or anticipated pregnancy during the course of the study
efficacy of monotherapy vs combination therapy of corticosteroids with gcsf in severe alcoholic hepatitis patients.

Conditions: Alcoholic Hepatitis

Summary: the patients of severe alcoholic hepatitis (sah) will be included in study based on inclusion and exclusion criteria. the patients will be then randomized in 3 groups for therapy. they will receive either steroid or granulocyte-colony stimulating factor (gcsf) or both. they will be followed for atleast 90 days for improvements in symptoms and various predefined parameters. primary outcome will be improvement in survival at 90 days. patients will be monitored at every follow up for disease progression and complications of therapy. the study results will be analyzed for differences in survival rate and complications in different groups to propose new therapeutic guideline in sah patients.


Eligibility criteria:
inclusion criteria: * severe alcoholic hepatitis patients \[maddrey's score \> 32\] aged between 18 to 65 years. exclusion criteria: * presence of active infections * acute gastrointestinal bleed * hepatorenal syndrome * patient unwilling * discriminant function \>90 * autoimmune hepatitis * hepatitis b, hepatitis c, human immunodeficiency virus cases * pregnancy * hemophagocytic lymphohistiocytosis (hlh) * hb\ 25000
a study in subjects with retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: an open-label phase ii clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including p23h) will be identified and treated with serial intravitreal injections of adx-2191 in the worse seeing eye. ocular structure and function will be evaluated.


Eligibility criteria:
inclusion criteria: 1. up to 8 adult patients age 18 or older 2. diagnosis of retinitis pigmentosa due to rhodopsin gene mutation, including p23h 3. impairment on visual field as determined by perimetry exclusion criteria: 1. age \< 18 years 2. pregnant 3. previous inflammatory/infectious events involving the eyes

Keywords: adx-2191 methotrexate retinitis pigmentosa rhodopsin mutation p23h